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Abstract 
Computerised tomography based radiotherapy workflow is limited by poor soft tissue 
definition in the pelvis and reliance on rigid registration methods. Current image guided 
radiotherapy and adaptive radiotherapy models therefore have limited ability to improve 
clinical outcomes. The advent of magnetic resonance image guided radiotherapy solutions 
provides the opportunity to overcome these limitations with the potential to deliver online 
real time magnetic resonance imaging based plan adaptation on a daily basis, a true “plan of 
the day”.  This review describes the application of magnetic resonance image guided 
radiotherapy in two pelvic tumour sites likely to benefit from this approach. 
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Abstract 
Computerised tomography based radiotherapy workflow is limited by poor soft tissue 
definition in the pelvis and reliance on rigid registration methods. Current image guided 
radiotherapy and adaptive radiotherapy models therefore have limited ability to improve 
clinical outcomes. The advent of magnetic resonance image guided radiotherapy solutions 
provides the opportunity to overcome these limitations with the potential to deliver online 
real time magnetic resonance imaging based plan adaptation on a daily basis, a true “plan of 
the day”.  This review describes the application of magnetic resonance image guided 
radiotherapy in two pelvic tumour sites likely to benefit from this approach. 
 
Introduction 
Multiple challenges exist in radiotherapy (RT) delivery for gynaecological and rectal targets. 
The target consists of volumes encompassing the primary tumour and elective nodal 
regions, which are difficult to visualise on Computerised tomography  (CT) and move 
independently of each other. Tumour targets are highly mobile deformable structures and 
are influenced by adjacent rectal and bladder filling, which is difficult to standardise 
throughout treatment. Substantial tumour regression can occur, which results in normal 
tissue falling into high dose regions, and extended field treatments are susceptible to 
rotational set up error (1). Intensity modulated radiotherapy (IMRT) reduces dose to normal 
tissue in gynaecological and rectal radiotherapy (2, 3), but tight conformity and sharp dose 
gradients mean that adequate planning target volume (PTV) safety margins to account for 
geometric uncertainty are essential to avoid a geographical miss. 
 
The current PTV margins applied to targets are based on margin recipes that aim to ensure 
95% of the prescribed dose is delivered to 99% of the target volume (4), or 95% of the 
prescribed dose is delivered to 100% of the target volume in 90% of patients (5). Significant 
inter-patient variability in target motion results in population-based margins that are much 
larger than necessary in most patients and still miss the target in a small number of cases.  
The alternative to large margins and increased normal tissue dose is to individualise margins 
and implement adaptive treatment strategies.  
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RT is currently planned on a single CT dataset obtained at treatment simulation. This may 
not reflect target and organ at risk (OAR) geometry at the time of treatment delivery. 
Adaptive radiotherapy (ART) uses information from imaging acquired before or during 
treatment delivery to modify the treatment plan based on changes in individual target and 
OAR geometry and biology. Adaptive strategies are classified based on their timescale 
relative to patient treatment (6). Offline strategies occur between treatment fractions and 
typically involve a single or multiple re-plans. Online adaptation is based on imaging 
acquired immediately prior to treatment and can be used daily or intermittently.  In on-line 
adaptation, tumour target and OAR interfraction changes are accounted for, which means 
that PTV margins can be significantly reduced (7). Adaptive strategies can also use 
information from previous treatment imaging to track the actual dose delivered to the 
tumour target and OARs and correct for any discrepancy between the planned and delivered 
dose distributions (8). Implementation of online adaptive strategies is limited by technical 
challenges, which include image quality, image registration, target and OAR segmentation, 
and plan re-optimisation. All of which, must be performed whilst the patient remains on the 
treatment couch in treatment position. 
 
Currently, Image guided radiotherapy with cone beam CT (CBCT) is limited by its ability to 
visualise the target and OARs and by artifact from moving gas. Magnetic resonance imaging 
(MRI) is the gold standard imaging modality for diagnosis and staging in gynaecological and 
rectal cancer and transition from CT-based to MR-based workflow in these tumour sites 
offers immediate advantages. MRI-guided RT (MRIgRT) will provide superior image quality at 
treatment planning and treatment delivery for image registration and target and OAR 
localisation and segmentation. This will facilitate implementation of online adaptive 
strategies to reduce normal tissue irradiation, whilst improving target coverage. The purpose 
of this article is to review the advantages and challenges in the clinical application of MRIgRT 
in radiotherapy treatment planning and treatment adaptation using rectal and 
gynaecological cancers as illustrative examples.   
 
Search/ selection strategy 
PubMed was searched using terms  "Rectal Neoplasms/radiotherapy"[Mesh] or "Uterine 
Cervical Neoplasms/radiotherapy"[Mesh] or "Endometrial Neoplasms/radiotherapy"[Mesh] 
and "motion" or  "adaptive" or "MR-guided" or "auto segmentation" or "auto contouring". 
Search included meeting abstracts and was limited to English language. Further references 
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were identified by cross-reference of articles. Identified studies were first screened by title 
and/or abstract, with further full paper screening to generate the final list of studies relevant 
to the scope of the present review. The last PubMed search was performed on 5th April 
2018. 
 
Rationale for MRI-guided adaptive radiotherapy (MRIgART) in gynaecological and rectal 
cancer 
MRI is the imaging modality of choice for diagnosis and staging in gynaecological and rectal 
cancer where it characterises tumour and local macroscopic extent to inform treatment 
decisions, assess treatment response and detect recurrent disease (9-11). It is essential in 
identifying patients for radiation treatment, determining the radiation treatment field 
extent and accurate definition of the tumour target from bladder, sigmoid and small bowel. 
 
1. MRI improves target localisation 
Target volume delineation on the planning CT in both gynaecological and rectal tumours is 
difficult because it is not possible to discriminate between tumour and normal tissue. 
Figures 1 and 2 illustrate improved soft tissue contrast seen on MRI compared to CT for RT 
treatment planning in rectal and cervix cancer. Compared to CT, target volume delineation 
on MRI results in significantly smaller rectal and cervix volumes (12, 13) and low inter-
observer variability in (14, 15). Studies evaluating inter and intra-observer variability in 
contour delineation on MRI in gynaecological and rectal radiotherapy are illustrated in tables 
1 and 2 (12-23). In rectal radiotherapy MRI delineation results in significantly reduced 
tumour length, width and distance of the proximal tumour edge to the anal verge p<0.05 
(12). When GTV is subdivided into tumour located in the sigmoid, rectal and anal sub 
regions, coverage of the CT contoured GTV was inadequate for tumours with MRI evidence 
of sigmoid or anal invasion (20).  
 
In cervix cancer, geometric studies show that agreement between target volumes delineated 
on transverse and para-transverse planes of MRI is good with conformity index 0.71- 0.72 
(19). In dosimetric studies, overestimation of tumor width on CT results in significant 
differences in the volume treated to the prescription dose or higher (13, 24). Compared to 
the CT-based imaging RT workflow, MRIgRT will provide superior visualisation of the target 
and normal tissue immediately before and during treatment delivery.  
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2. MRI for motion assessment  
Extensive target motion occurs in gynaecological and rectal radiotherapy and has been 
reviewed previously (25, 26). With radiotherapy for cervix cancer, the primary clinical target 
volume (CTV) includes any visible tumour, cervix, uterus, upper vagina and parametrium. 
The elective nodal CTV includes the pelvic and common iliac lymph nodes (LN) and the para-
aortic LN in high-risk disease.  Motion is largest at the uterine fundus and studies report 
maximum interfraction motion of over 3 cm (27). In one study, margins of 15 mm to the 
primary and nodal CTV failed in 32% of patients and margins of up to 30 mm were required 
to ensure coverage in 95% of fractions (27).  
 
With radiotherapy for rectal cancer the primary target volume includes the tumour and 
mesorectum, and the elective nodal volume includes the pelvic LN. The entire circumference 
of the rectum at the level of the tumour is included, because it is not possible to distinguish 
tumor from normal rectal tissue on CT. The anterior and lateral rectal wall move more than 
the posterior wall and motion is larger in the middle and upper rectum compared with the 
lower rectum (28).  Maximum motion occurs anteriorly, particularly in the upper 
mesorectum, and anterior PTV margins of 24 mm in the upper mesorectum and 15 mm in 
the lower mesorectum have been recommended (29, 30). Tables 3 and 4 summarise the 
published data for cervix and rectal interfraction target motion. (27, 28, 31-43) 
 
Bladder and rectal filling influence target motion in gynaecological and rectal radiotherapy. 
With cervix treatment, bladder volume is correlated with superior/inferior uterine motion 
and rectal volume is correlated with cervix and vaginal anterior/posterior motion (33). With 
rectal radiotherapy, deformation of the mesorectum is largely driven by changes in rectal 
volume (29).  In both cervix and rectal radiotherapy there is significant inter-patient 
variation in bladder volume despite bladder filling protocols, and both bladder and rectal 
volumes reduce during treatment (27, 28, 34, 44). Laxatives may not significantly reduce 
target anterior/posterior motion from rectal volume variation, because passage of gas can 
still cause significant target displacement (37). Figure 3 illustrates CTV positional changes 
related to bladder volume as seen on CBCT during cervix radiotherapy. MRIgART will 
facilitate implementation of margin reduction through adaptive strategies that account for 
these geometric changes. 
 
3. MRI for anatomical response assessment and dose escalation 
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Significant tumor regression is observed during cervix and rectal radiotherapy (31, 34, 45, 
46). In 20 cervix patients having weekly MRI during chemoradiotherapy (CRT), average 
tumour volume reductions of 59.6% at week 4 were observed, which resulted in increased 
uterine motion, substantial changes in tumor position and movement of normal tissue, 
particularly small bowel, into the high dose region (47). Repeat MRI and planning after 
delivery of 30 Gy found that a second IMRT plan significantly reduced the volume of bowel 
irradiated if the primary gross tumor volumes decreased >30 cc (47).  
 
In a study of 15 rectal cancer patients, mean tumour regression of 46.3% was seen on MRI 
by week 5 of CRT and regression was fastest in the 1st 3 weeks of treatment (45). A further 
study in 13 patients found that the majority of patients who had a good response to 
treatment had volume reduction and fibrotic changes during weeks 1-3 (46). There is a move 
towards organ preservation in rectal patients with a complete radiological response to spare 
morbidity from surgery (48). Patients who respond to CRT are more likely to benefit from 
dose escalation to increase the rate of pathological complete response (pCR) (46) and early 
assessment to identify these patients is therefore important. Response to neo-adjuvant CRT 
is dose-dependent with dose escalation of >60 Gy resulting in increased rates of pCR and 
acceptable toxicity (49). Tumour boost volume delineation on the initial radiotherapy 
planning CT does not take account of tumour regression during treatment. Repeat imaging 
during treatment could help select patients who would benefit from radiation dose 
escalation and would produce more accurate and smaller boost volumes, facilitating 
increased tumor dose without increased OAR dose and toxicity (50). 
 
Figures 4 and 5 illustrate changes in cervix and rectal tumour volume as seen on weekly MRI 
during radiotherapy. 
 
4. MRI for biological response prediction and dose delivery assessment 
Functional MRI with diffusion-weighted imaging (DWI) and dynamic contrast enhancement 
(DCE) may predict biological response in rectal and cervix radiotherapy and identify patients 
for dose escalation (14, 51). 
 
MRI has potential to act as a biomarker, identifying good and poorly responding tumours to 
select patients for dose adaptation in order to improve treatment outcomes (52-55). Studies 
suggest that diffusion weighted images (DWI) can predict pathological complete response 
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early in rectal radiotherapy (53, 54, 56, 57), but there are limitations to the current evidence 
preventing its routine implementation in patient selection for dose escalation. Most studies 
were small and did not prospectively determine MRI criteria to differentiate between 
complete and non-complete response to treatment. Retrospective identification of these 
parameters introduces selection bias. There was variability in the time-points at which 
imaging was acquired and surgery was performed. For example patients classified as 
achieving a non-pCR at 6 weeks following CRT, may have been classified as a pCR if surgery 
was performed at a later date and meta-analysis reports 6% increase rate of pCR with an 
interval of greater that 6 weeks from the end of preoperative CRT (58). 
 
In cervix radiotherapy DCE and DWI MRI may predict response to CRT and identify patients 
for dose escalation (51). Increasing apparent diffusion coefficient (ADC) values from DWI 
acquired during treatment can detect early signs of treatment response (55). DCE MRI 
during treatment detects tumour perfusion (59).  Persistently low perfusion during CRT is 
correlated with treatment failure and patients with increases in perfusion during CRT have 
better outcomes (59). This could identify patients for dose escalation to hypoxic regions, 
which should increase tumour shrinkage prior to brachytherapy, which we know improves 
local control (60). There was however, no technical standardisation in these studies, which 
limits assessment of reproducibility and generalisability. The optimal time to assess 
biological response and adapt treatment based on these finding has yet to be determined. 
 
MRIgRT will also provide quantitative knowledge of the actual delivered dose and the impact 
of radiation dose on tumour and normal tissue. This would enable dose compensation 
strategies and tumour and normal tissue radiobiological modeling.  
 
Adaptive radiotherapy (ART) strategies  
1. Target volume modification based on individual internal motion 
PTV modification based on data from set up and internal target motion acquired from 
planning or previous treatment, allows safe reduction of generic population based margins. 
This is also referred to as a composite volume technique. The range of target motion is 
modelled during the planning stage or first treatments to generate an internal target volume 
(ITV). The treatment plan is optimised off-line and applied to subsequent treatments. 
Individualised ITVs in cervix radiotherapy account for the range of cervix and uterine motion 
with variable bladder volume and may be based on variable bladder filling CT scans acquired 
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at simulation or using bladder geometry as a predictive tool (61, 62). Compared to 
population-based margins, individualised margins reduce CTV-PTV margins by 48% (+/- 6%), 
and bladder and rectal volume within the PTV is reduced by 5-45% and 26-74% respectively 
(62). 
 
For rectal cancer an average CTV can be acquired from the radiotherapy planning (RTP) CT 
and repeat CTs during the 1st week of treatment (30). Adaptation after day 4 resulted in a 7 
mm reduction in the maximum required PTV margin from 24 to 17 mm and a significant 
reduction in PTV and dose to the small bowel (30).  
 
2. On-line plan selection strategy 
On-line plan selection uses imaging acquired at treatment to select a plan from a library of 
treatment plans generated from multiple PTVs. In cervix radiotherapy, evaluated strategies 
include a plan library using individualised PTVs based on CTV position at different bladder 
volumes, or PTVs created by the application of incremental margins to the CTV as seen on 
RTP CT acquired with a full bladder (62, 63). Compared to a standard population margin 
approach, plan selection results in significantly better target coverage and OAR sparing (62-
64).  Adaptation based on variable bladder filling CTVs enables reductions in PTV margins 
from 38 mm to 7 mm and better CTV D98%> 95% in comparison to the non-ART approach 
where 17% of treatment fractions have inadequate target coverage (62, 64). When using an 
incremental margin approach, a 5 mm margin of the day plan could be used in 25% of 
fractions (63). Libraries based on variable bladder filling do not account for rectal filling 
variation or the passage of gas, which are difficult to predict and can significantly influence 
cervix motion (65). 
 
In rectal cancer, target motion is influenced more by rectal than bladder filling, so a library 
of plans strategy based on variable bladder volumes is not appropriate. Instead plan 
selection has been based on plans with variable PTV margins between -25 mm and + 25mm 
applied to the anterior CTV, which is where largest variation is seen (66). This reduced dose 
to the bladder and small bowel OARs, although the absolute reductions were small (67).  
Plan selection in rectal radiotherapy is feasible with good plan selection consistency 
between observers of 75% (66). Plan selection in both cervix and rectal radiotherapy is being 
implemented clinically, but is limited by the image quality of CBCT. MRIgRT would facilitate 
target and OAR localisation for on-line plan selection. 
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3. Plan re-optimisation  
The optimal strategy to account for target and OAR motion and deformation, anatomical 
and biological response, is to generate a new plan with full re-optimization. This determines 
the dose distribution based on target and OAR geometry and/or physiology at the time of 
treatment delivery (6).  
 
A number of planning studies in cervix radiotherapy have simulated the benefit of on-line re-
planning (7, 68, 69). One study of 33 patients compared a 3 mm PTV margin plan without re-
planning, with an automated weekly re-plan on real time patient geometry as seen on MRI 
(68, 69). Pre-treatment optimisation criteria were automatically re-applied to re-plans 
without any physics planner intervention. Without re-planning, there was a significant 
reduction in accumulated dose to the primary CTV, with 9 patients failing D98%> 95% (68). 
In patients who were re-planned there was a reduction in CTV between 8-68% (median 39%) 
and the D98 CTV constraint was met in all patients (68). There was no difference in dose to 
OARs, which might move with the target and remain in the high dose region. This may lead 
to increased OAR dose in patients where OAR movement is related to the target compared 
to patients where the OARs move independently (68, 69).  
 
A study in 14 cervix patients used 15 mm PTV margins and re-planning based on target and 
OAR geometry on MRI after 30 Gy (47). There was a reduction in OAR dose with re-planning, 
but in this study the re-plans were interactively optimised to reflect new anatomy (47).  A 
planning study to simulate the benefit of online MRIgRT re-planned used weekly MRI in 11 
patients receiving IMRT for cervix cancer with 4mm PTV margins (7). This was compared to 
plans based on the pre-treatment MRI with primary and nodal PTV margins of 15 and 10 mm 
(7). There was a significant reduction in the dose to the bladder, rectum, sigmoid, and small 
bowel with online re-planning (7). 
 
4. Dose compensation 
Adaptation using dose tracking allows reduction in PTV margins because variations in the 
dose delivered to the CTV compared to the planned dose, can be compensated for in 
subsequent fractions. The pre-treatment imaging, together with any set up correction 
applied, is used to determine target and OAR position and the dose delivered at each 
treatment fraction. This is non-rigidly registered to the planning CT to model anatomical 
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motion and deformation and allows calculation of the accumulated delivered dose. The 
treatment plan can then be re-optimised to compensate for any problems with dose 
coverage or to account for adaptation of treatment goals.  
 
Lim et al looked at pre-treatment and weekly MRI in 30 cervix IMRT patients using a 3mm 
PTV margin and dose accumulation (70). They modelled an anatomical driven approach with 
a single off-line re-plan mid-treatment to account for tumour regression, and a 
dosimetrically triggered approach if the estimated accumulated D98 to the GTV or primary 
CTV was low. Without re-planning, there was insufficient target coverage in 27% of patients. 
The anatomical approach improved target coverage and reduced OAR dose, but there were 
still 3 patients with insufficient target coverage. Dosimetrically triggered re-planning 
resulted in target coverage in all patients, but no difference in the accumulated OAR dose 
(70). Deformable registration is not consistently accurate and validation is difficult. In 
deformable registration for dose accumulation, particular caution must be taken when 
tumours have undergone mass change and in areas with sharp dose gradients. 
 
Integration of MRI into radiotherapy and its challenges 
MRI can be integrated into radiotherapy workflow in a variety of ways. In a CT-MRI 
simulation workflow, the MRI is used for contour delineation at radiotherapy treatment 
planning (RTP) and the CT provides a robust geometric representation of the patient, an 
electron density map required for dose calculation and a reference image for patient set up 
during standard treatment. Any error in image registration will however lead to a systematic 
geometric error throughout patient treatment (71). MRI-only simulation reduces potential 
for image registration error at RTP, but the challenges of geometric distortion and lack of 
electron density information and material properties inherent to MRI need to be addressed. 
MRI for radiotherapy treatment localisation, planning and verification have different 
demands to those acquired for diagnosis and staging. Specific solutions are required.  The 
main differences relate to patient positioning, image acquisition and sequence parameters 
and the need for geometric accuracy (Table 5).  
 
A number of MRIgRT technologies are in active development, integrating MRI with external 
beam radiotherapy delivery, providing MRI data immediately before and after treatment, 
and simultaneously with treatment delivery (72-75). They differ in their imaging and 
treatment adaptation capabilities and their approach to tackling the technical challenges of 
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magnetic and radiofrequency interference and treatment beam transmission through the 
magnet. Table 6 summarises the different systems, each presenting advantages and 
disadvantages (72, 74-77). The MRIdian system (ViewRay Inc, Oakwood Village OH) has 
treated over 300 patients since 2014 and integrates a 0.35 Tesla (T) magnet with either 
three multileaf collimator (MLC)-equipped Cobolt-60 heads, or a 6 MV linac with one MLC 
(73, 78). The Elekta Unity MR-linac solution (Elekta AB, Stockholm, Sweden) started treating 
patients in 2017 under pre-CE mark clinical trial protocol. It integrates a 7 MV linac with a 
high field 1.5 T MR imaging system from Philips, which uses technology similar to the Philips 
Ingenia diagnostic systems (72). Lower magnetic field solutions benefit from a reduction in 
image artifacts and patient related geometric distortion, and lower energy deposition by the 
radiofrequency pulses. Higher field solutions benefit from enhanced signal to noise, which 
improves spatial and temporal resolution and functional imaging capabilities.  
 
Technical challenges in the realisation of real-time MRIgART  
Generation of a new treatment plan based on target and OAR geometry or biology at the 
time of treatment delivery is the ultimate goal of MRIgART. The main challenge is achieving 
this in a short amount of time with the patient on the treatment couch. Its clinical 
implementation is limited by; 
1. Requirement for robust automated real-time registration of the newly acquired MRI 
with the images used for treatment planning 
2. Requirement for electron density data necessary for dose calculation 
3. Target and OAR segmentation on the new MRI 
4. Plan re-optimisation and dose calculation 
5. Quality assurance of the newly generated plan.   
 
Image registration and approaches to generate electron density information for MRIgRT 
have been discussed in our previous review. In the first clinical applications of MRIgART 
using the Elekta Unity MR-Linac (Elekta AB, Stockholm, Sweden) and the MRIdian system 
(ViewRay, Oakwood Village, OH), MRI are acquired immediately before treatment and 
registered to the reference planning MRI and planning CT using deformable registration (79, 
80). Electron density information from the reference planning CT is then transferred to the 
MRI of the day using the deformation map (79, 80). 
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The standard treatment-planning process requires segmented contours and generates the 
desired dose distribution from scratch. This is achieved through iterative optimisation, 
driven by defined objective functions set by the planner, which specify the dose volume 
constraints for tumour targets and OARs. The planner then fine-tunes the objective 
functions and repeats the optimisation process to further improve the treatment plan by 
trial and error. This takes too long to be feasibly implemented in real-time MRIgART and 
faster automated re-planning strategies are required.  
 
Segmentation of target and OARs on the daily image is a major challenge in online re-
planning. Manual segmentation is time consuming and susceptible to inter and intra-
observer variability. Mean time required to manually delineate the pelvic nodal CTV alone is 
over 30 minutes, and automated strategies are necessary to reduce segmentation time and 
improve structure definition (81). Autosegmentation without prior knowledge uses imaging 
properties such as voxel intensities and gradients (82). Alternative strategies incorporate 
prior knowledge into the segmentation process to improve accuracy and reproducibility and 
include atlas-based segmentation, statistical shape models, machine learning and hybrid 
strategies (82).  
 
In atlas-based autosegmentation, an atlas of manually contoured structures is used to 
propagate structures onto a new dataset using deformable registration voxels 
transformations (83-85). Use of multiple atlases further improves accuracy (86). Cervix 
target segmentation on MRI using machine learning results in mean sensitivity and 
specificity of 85-93% (87) and is faster than atlas based strategies (88). Accuracy of 
autosegmentation is not perfect and visual verification is still required. In MRIgART using 
both the Elekta Unity MR-Linac and the ViewRay MRIdian systems, target and OAR contours 
are transferred to the online MRI from the reference image using deformable registration 
and are then checked and manually edited if necessary by a clinician (78, 80, 89). 
 
Daily plan re-optimisation does not need to start from scratch and many components of the 
new plan can be extrapolated from the original fully optimised plan. Plan modification with 
aperture morphing reduces the number of steps in reoptimisation (90). Segment aperture 
morphing adjusts the beam segment shape of the multi-leaf collimator, based on the new 
target position and shape, as seen in the projection from the beam’s eye view of each 
treatment beam. Segment weight optimisation can then be applied to improve dosimetry 
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(90). More complex aperture morphing methods rely on deformable registration (91, 92).  
 
Plan adaptation based on previous knowledge from the original plan can also speed up the 
process. Gradient maintenance strategies maintain the same dose gradient around the 
target, towards the OARs, as in the original treatment plan (93). This requires segmentation 
of the new target but not segmentation of OARS. It may not be suitable for the larger target 
volumes seen in gynaecological and rectal radiotherapy. Interactive dose shaping is based on 
contoured structures and enables direct manipulation of the initial plan isodose surface 
shape or the dose to individual voxels (94, 95). Advances in computer power, both graphical 
processing units and modified central core processing units, can now reduce the time of plan 
optimisation and dose calculation from minutes to seconds (96, 97). Commercial treatment 
planning systems incorporating advances in adaptive planning are now becoming available. 
 
Plan approval and quality assurance (QA) in real-time MRIgART is challenging.  Automation 
of image acquisition and registration, target and OAR segmentation, treatment dose 
calculation and adaptive planning optimisation is essential in implementing online MRIgART, 
but creates additional problems. The detailed plan reviews and QA process that occur at pre-
treatment during standard radiotherapy are not appropriate.  Limiting physician plan 
approval to when plan quality is less than the original treatment plan would improve 
efficiency.  Conventional patient specific QA approaches insert physical phantoms in the 
treatment beam, which cannot be used with the patient on the treatment couch. An 
alternative solution is to send the treatment plan to an independent dose calculation engine 
to verify that the dose distributions agree (98).  
 
Delivery of MRIgRT with the ViewRay MRIdian Cobalt 60 was feasible in 11 rectal patients 
receiving neoadjuvant chemoradiation with IMRT and simultaneous integrated boost (99). 
Daily MRI were acquired for patient set up and verification, and all patients completed 
treatment. The ViewRay MRIdian has also been used for imaging and radiotherapy planning 
in brachytherapy for cervical cancer (100). No studies have yet been published for MRIgRT 
delivery in cervix external beam radiotherapy. 
 
Conclusions 
MRIgRT in rectal and gynaecological radiotherapy will improve all aspects of the treatment 
workflow. Its most exciting application in gynaecological and rectal radiotherapy will be to 
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refine GTV to CTV definition, increased accuracy and precision of target localisation for 
treatment verification and implementation of adaptive strategies to personalise the 
therapeutic approach. This will facilitate reduced PTV margins and normal tissue irradiation 
whilst maintaining target coverage. Together with dose adaptation, this will translate into 
improved tumour control and reduced toxicity for patients. Optimal adaptive strategies 
need to be determined and challenges remain for the implementation of MRIgART clinical 
workflow. But technology is exponentially increasing and the ability to personalise and 
intensify treatment with MRIgART at these tumour sites is no longer an improbable blue-sky 
ideology but is now within reach. 
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Figure 1. Radiotherapy planning imaging in a male patient with T3N1 rectal cancer; a) CT and 
b) MRI. On MRI the tumour (arrow) is easily differentiated from normal rectum, which is not 
possible on CT 
 
 
Figure 2. Radiotherapy planning imaging in stage 2B cervix cancer (a) CT and (b) MRI. On MRI 
the cervix tumour (arrow) is easily differentiated from normal bladder and rectum, which is 
not possible on CT 
 
 
Figure 3. Changes in clinical target volume position during cervix radiotherapy as 
seen on MRI at a) week 0, b) week 2, c) week 3 and d) week 4.  
 
Figure 4. Changes in cervix tumour volume (arrow), as seen on weekly MRI during 
treatment at a) week 0, b) week 2, c) week 3 and d) week 4.  
 
Figure 5. Changes in rectal tumour volume (arrow), as seen on weekly MRI during 
treatment at a) week 0, b) week 2, c) week 3 and d) week 4.  
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FSTable 1. Contour delineation on MRI for cervix cancer  
Ref No of 
patients 
Structures contoured/  
Contour guidelines used 
Method MR sequence Results 
13 
 
 
 
10 
 
HRCTV and IRCTV 
 
GEC/ESTRO guidelines 
MRI versus CT  
 
1 radiation oncologist 
 
  
T2w  
Axial 
 
HRCTV height, thickness and total volume were similar  
 
Significant difference in width of HRCTV and IRCTV on CT compared to MRI  
 
Significant difference in volume of HRCTV treated to prescription dose or more (MRI 96%, CT 86% 
p≤0.01)  
15 
 
3  GTV, nodal CTV, uterus and 
parametrium 
 
RTOG guidelines 
Inter-observer variability  
 
12 radiation oncologists 
 
 
T2w  
Axial 
High GTV agreement (sensitivity 0.54-0.92, specificity 0.97-0.98) 
 
Moderate agreement for nodal CTV, uterus and parametrium (kappa statistic 0.45-0.77 p<0 .0001) 
 
Contouring variability largest at cervix and vagina 
16 
 
1 GTV 
Cervix, uterus, vagina and 
parametrium 
 
RTOG guidelines 
Inter-observer variability  
 
19 radiation oncologists 
 
 
T2w 
Axial 
Good sensitivity and specificity for GVT (0.84 and 0.96 respectively) 
 
Moderate agreement for cervix, uterus and vagina (kappa 0.42–0.57 P<0.001)  
 
Parametrium good specificity 0.99 but low sensitivity 0.48  
17 
 
19  
 
 
GTV, HRCTV and/IRCTV  
 
GEC/ESTRO guidelines 
Inter-observer variability  
 
2 radiation oncologists 
T2w 
Axial 
No significant difference in mean volume of GTV and HRCTV p>0.05 
Significant difference in mean volume IRCTV p< 0.05 
 
Conformity indices (range); GTV 0.6 (0.1- 0.9), HRCTV 0.7 (0.4- 0.8) and IRCTV 0.7 (0.5- 0.8) 
18 
 
6 GTV 
HR-CTV 
 
GEC-ESTRO guidelines 
Inter-observer variability  
 
10 radiation oncologists  
T2w  
Axial 
Mean relative SD of 8–10% for GTV and HRCTV D90  
 
Mean relative SD for D2cc was 5–8% for rectum and bladder, 11% for sigmoid 
19 13 HRCTV 
 
GEC/ESTRO guidelines 
 
Inter-observer variability  
 
2 experienced observers 
 
T2w 
Transverse 
versus para-
transverse 
plane  
Interplane conformity index did not differ significantly between observers (0.72v 0.71)  
Interobserver conformity index between planes was not significantly different (0.79v 0.78) 
 
Contouring on para-transverse plane was quicker 
 
No significant difference in DVH of plans using contours from transverse or para-transverse planes 
23 20 Elective pelvic LN volume 
 
MRI with iron oxide 
particles to delineate LNs 
and establish pelvic LN 
contouring guidelines 
T2w with 
administration 
of iron oxide 
particles 
Blood vessels with a 7 mm margin, edited off muscle and bone,  are a good surrogate target for the 
elective pelvic LN volume 
HRCTV= High risk clinical target volume 
IRCTV= Intermediate risk clinical target volume 
GTV= Gross tumour volume 
Table 1
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FSTable 2. Contour delineation on MRI for rectal cancer  
Reference No of 
patients 
Structures 
contoured 
Method MR sequence Results 
12 
 
10 GTV (entire 
rectal wall 
at level of 
tumour) 
MRI v CT 
(MR<2-3/52 from CT) 
 
1 radiologist 
 
T2w sagittal  
 
CT overestimated all tumour radiological parameters 
 
Mean MRI GTV volume 18 cm3 smaller than on CT p<0.05 
 
Mean MRI GTV length, max width and distance of proximal tumour to anal verge significantly less 
than on CT (mean reduction 3.2 cm, 0.5 cm, 2.9 cm respectively) p<0.05 
20 
 
15 GTV 
 
MRI V CT 
 
1x radiologist in 
consultation with 1x 
radiation oncologist 
T2 axial 
 
Mean CT-GTV/ MRI- GTV volume ratio was 1.2cc (range 0.5- 2.9)  
 
CT-GTV coverage inadequate for tumours with sigmoid or anal invasion and in the 2 cases this 
occurred there was significant underestimation of GTV on CT. 
14 
 
24 GTV MRI T2 v DWI 
 
Inter-observer variation 
 
3 radiation oncologists 
 
T2w, DWI and a 
combination of 
both  
 
Axial 
T2 GTV volumes significantly larger than on DWI (approx. 2-3 x larger) 
 
No significant difference between observers per modality (mean conformity index 0.7 for T2w and 
0.71 for DWI) 
 
Mean distance between contours T2= 1.8 mm and DWI= 1.5 mm 
21 
 
27 GTV MRI T2w v DWI 
 
Inter-observer variation 
 
2 radiologists 
 
T2w v DWI axial T2W MRI GTVs were slightly larger but not statistically different from DWI volumes 
 
Inter-observer mean difference in volume was not improved with DWI 
 
Mean difference and 95% limits of agreement for T2W MRI and DWI GTVs were -9.8 (-55 to 35) cm3 
and -14.8 (-54 to 24.4) cm3 respectively. 
22 50 GTV MRI pre and post CRT 
 
Inter-observer variation 
 
2 radiologists 
 
Histology reference 
standard for post CRT 
radiology 
Pre and Post 
CRT DWI and 
T2w MRI axial 
Pre CRT MRI; Inter-observer agreement for T2w and DWI was excellent (ICC 0.97)  
 
ICC all modalities; pre CRT 0.91- 0.96 and post CRT 0.61- 0.79 
 
ROC for post CRT volume T2w= 0.7, DWI= 0.93 and ADC=0.54 
GTV= Gross tumour volume 
CRT= Chemoradiotherapy 
ICC= intraclass correlation coefficient  
ROC = receiver operating characteristic  
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Table 3 Interfraction motion in cervix cancer radiotherapy 
 
Ref Target 
Measured 
No 
of 
Pts 
Imaging 
modality and 
Frequency 
Method of 
measurement/ 
registration 
Statistic used Motion (mm) Suggested Margins (mm) Volume change Bladder/ rectum 
correlation 
AP LR SI AP LR SI   
31 Cervix  16 Weekly CT 
 
 
Cervix COM  
 
 
Cervix contour  
Mean max 
Range 
 
Mean max 
16 
5.1-25 
 
A=17 P=18 
8.2 
4.4-14 
 
L=9.4 R=7.6 
21 
12-33 
 
S=23 I=13 
   Cervix volume reduced by 
mean 62.3% after 45Gy  
 
Bladder volume affects AP 
and SI but not lateral 
margins 
32 Cervix 
Uterus 
 
20 MR at 
baseline and 
weekly x5 
 
 
Cervical os 
Uterine canal 
Uterine fundus 
 
Cervical os 
Uterine canal 
Uterine fund us 
Grand mean 
 
 
Mean range 
2.4 
-4.8 
-4.6 
 
11.2 
13.1 
14.5 
 
 
1.5 
5.7 
7.8 
 
11.3 
15.7 
24.4 
Isotropic internal margin to 
encompass 90% of motion was 
40 mm at the fundus and 15 mm 
at the cervix 
Significant reduction in 
bladder volume during RT. 
 
No systematic change in 
rectosigmoid volume.  
Bladder volume associated 
with SI motion of fundus 
and AP motion of cervical 
os. Rectal volume 
associated with SI motion 
of uterine canal and 
cervical os. 
33 Cervix 
Uterus 
Upper 
vagina 
33 MR on 2 days 
24hrs apart 
Post cervix 
Uterine body 
Upper vagina 
Mean (SD) 
 
CTV-PTV 
margins  
2.7 (2.8) 
7 (9) 
2.6 (3) 
0.3 (0.8) 
0.8 (1.3) 
0.3 (1) 
4.1 (4.4) 
7.1 (6.8) 
 
15 
30 
11 
7 
8 
13 
25 
7 
 SI uterine motion 
correlated to bladder 
filling.  
AP cervix and vaginal 
motion related to rectal 
filling 
34 GTV  
CTV 
20 MR at 
baseline and 
weekly 
 
 
GTV 
 
 
CTV 
Margin to 
encompass 95% 
cases (internal 
motion) 
 
   A=12 
P=14 
 
A=24 
P=17 
R=12 
L=11 
 
R=12 
L=16 
 
S=4 
I=8 
 
S=11 
I=8 
Significant regression GTV 
p≤0.001 
 
Mean GTV 57cc week 0, 
43.3cc, 32cc and 23cc at 
weeks 2, 3 and 4 
AP shift in GTV and CTV 
weakly correlated with 
rectal vol. 
Significant difference in 
margins required if pre-
treat rectum volume > 70 
cc. 
27 CTV 10 Daily CBCT 
 
 
COM 
 
Mean 
SD 
Range 
3 
5 
-9.4-18.9 
-0.28 
1.3 
 +3.3- 3.5 
-4.6 
3.9 
-15.3- 3.8 
Mean margin to encompass CTV 
motion=15 mm, but fails in 32%  
 
Margins up to 30 mm could be 
required to ensure coverage in 
≥95% fractions. 
Mean reduction in CTV of 
20% (586.4 to 469cc) 
 
Mean bladder volume 
relative to the planning CT  
-48.5 cc  
Increased rectal and 
bladder volume associated 
with significant superior 
shifts  
 (P<0.001) 
35 Cervix 10 Daily EPID  
 
 
Cervix fiducials 
 
 
Mean of mean 
Random error 
Internal motion 
3.5 
3.9 
3.7 
2.2 
4.1 
3.7 
 
 
9.7 
 
 
10.8 
 
 
8.9 
  
36 Cervix 15 Portal films 
weekly 
Radiopaque 
ring 
Median 
Max 
16 
23 
10 
24 
8 
36 
   50% reduction in tumour 
size at 30Gy (21 days) 
 
37 Cervix 10 Daily 2D kvi 
 
Cervix fiducials 
 
Mean 
SD 
Max 
4.2 
3.5 
18 
1.9 
1.9 
14 
4.1 
3.2 
18 
     
38 Cervix 10 MVCT daily Cervix contour 
 
Uterus contour 
 
95% margin for 
internal motion 
and set up  
Mean 
SD 
Mean 
SD 
A=0.4  P=-3 
A=10.1  P=6.9 
A=3.3  P=0.3 
A=11.9 
P=11.7 
L=-3.5 R=0.2 
L=4.9 R=4.5 
L=0.7 R=-0.6 
L=8.1 R=7.5 
S=2.2 I=0.5 
S=8  I=5 
S=6.1 I=5 
S=11.6 I=11.2 
A=17 
P=12 
 
 
A=19 
P=19 
R=8 
L=9 
 
 
R=13 
L=13 
 
S=15 
I=9 
 
 
S=20 
I=19 
Significant reduction in 
mean cervix volume 
(106 cc pre-treatment to 
74 cc last week of 
treatment)  
Average bladder volume 
reduced from 156 cc in 
wk1 to 88 cc in the last 
week (p < 0.01). 
39 Cervix 20 MRI baseline 
and weekly 
x5 
GTV 
Cervix 
Uterus 
Euclidean 
vector 
displacement  
1.2 +/- 0.4 (0.5-3) 
1.1 +/- 0.3 (0.5- 2.8) 
1.7 +/- 0.2 (0.5- 4.5) 
15mm GTV to PTV margin 
covered the GTV to >98% of 
prescription dose 
The relative reduction in 
the GTV from baseline to 
the end treatment was 
Individually, the planned 
dose was not the same as 
the simulated delivered 
Table 3 
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 Upper vagina  0.7 +/- 0.3 (0.3- 1.3) 48–96%.  dose 
 
 
 
 
BJ
R U
NC
OR
RE
CT
ED
 PR
OO
FS
Table 4 Inter and Intrafraction motion in rectal cancer 
Ref Target 
Measured 
No 
of 
Pts 
Imaging 
modality and 
Frequency 
Method of 
measurement/ 
registration 
Statistic used Motion (mm) Suggested Margins (mm) Volume change Other 
AP LR SI AP LR SI   
40 
 
GTV 
Rectum 
Mesorectum 
17 RTP CT Wk1, 3 
and 5 
Displacement of 
points on GTV, 
rectum and 
mesorectum 
surface  
Mean (SD) 
GTV 
Rectum 
Mesorectum 
 
 
0.7 (3.1) 
1.1 (5.1) 
1.1 (2.7) 
 
-1.2 (2.8) 
-0.2 (4.5) 
-0.3 (2.2) 
 
 
4.2 (3.6) 
 
A=14 P=7 
A=8 P=9 
A=7 P=6 
 
 
L=7 R=8 
L=8 R=8 
L=5 R=4 
 
S=16 I=12 
 
 Greatest motion of rectum in 
upper 1/3 
 
No correlation of motion 
direction and bladder filling 
41 
 
Mesorectum 
 
 
10 Helical MVCT 
before and 
after treatment 
x2/week 
Contour 
displacement by 
bony landmarks 
 
 
Mean (SD) 
 
Margins for 
intrafraction 
motion and set 
up 
A=-2(6.8) 
P=-0.4 (3.8) 
L=-1.6(4.2) 
R=0.1(4) 
S=-3.2(5.6) 
I=-3.2(6.8) 
 
A=11 
P=7 
8 S=10 
I=12 
 If new margins applied 
instead of standard 1 cm 
margins, there would be an 
average decrease in PTV by 
21.5% (SD, 1.45%). 
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Rectum 16 CBCT D1-3, then 
weekly 
 
 
GTV to PTV 
margin 
Upper rectum 
 
 
Mid rectum 
 
 
Low rectum 
Mean of mean 
Mean of SD 
 
Mean of mean 
Mean of SD 
 
Mean of mean 
Mean of SD 
A= -4     P=-0.1 
A= 7.4   P= 4.2 
 
A= -1    P=-0.1 
A=  7    P= 3.6 
 
A= 1.8    P= 1.2 
A= 4.2   P= 4.7 
L= 1.3  R=-2.8 
L= 6.9  R= 5.2 
 
L= -0.4 R= 0 
L=  5.1 R= 4.1 
 
L= 0.1 R= 0.0 
L= 3    R= 3 
 A=17 
P=14.4 
 
A=16.7 
P=14.9 
 
A=14.2 
P=16 
L=4.2 
R=4.2 
 
L=11 
R=10.3 
 
L=9 
R=10.1 
 No significant 
change in rectal 
volume on 
CBCT compared 
to baseline CT 
No relationship between 
rectal and bladder volume 
and time 
 
Significant day to day 
bladder volume variation  
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CTV  
Rectum 
10 Weekly RTP CT 
 
 
 
CTV 
 
Rectum 
At AV 
5.5cm from anus 
9cm from anus 
 
 
 
At anus 
4.5cm from anus 
9cm from anus 
CTV SD of 
motion 
 
 
 
 
 
Rectum SD of 
motion 
A=3-4 
A=6 
A=10 
 
P= No motion  
 
P=4 
P=7 
P=2 
 
A= ‘very similar 
to CTV’ 
No motion 
observed 
 
 
 
 
Motion similar 
to CTV, ie. no 
motion 
     Motion dependent on 
location in pelvis 
 
Increased motion of CTV at 
≥5.5cm from anus caused by 
bladder filling 
 
Biggest motion at 10 cm 
from anus 
 
The biggest difference in CTV 
volume between a full and 
empty bladder was 51 cm3  
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Mesorectum 63 Repeat RTP CT 
 
LCRT daily CT 
for 1st week and 
then weekly. 
 
SCRT cohort 
daily CT 
 
LCRT 
Upper 
Mesorectum 
Lower 
mesorectum 
 
SCRT 
Upper 
Mesorectum 
Lower 
Mesorectum 
 
PTV margins for 
95% prescribed 
dose to 90% 
patients 
 
 
    
A= 24 P=7 
 
A=15 P=7 
 
 
 
A=32 P=7 
 
A=18 P=7 
 
L=7 R=7 
 
L=7 R=7 
 
 
 
L=7 R=7 
 
L=10 R=10 
 
S=10 I=10 
 
S=10 I=10 
 
 
 
S=10 I=10 
 
S=10 I=10 
 
Significant 
reduction in 
rectal volume in 
LCRT by 35% 
 
Reduced 
bladder volume 
during RT 
 
Significant reduction in rectal 
volume resulted in 5 mm 
post shift of upper ant CTV 
 
Table 4 
BJ
R U
NC
OR
RE
CT
ED
 PR
OO
FSTable 5: Different demands of MRI acquired for diagnostic and radiotherapy purposes in cervix and rectal cancer   
 MRI for diagnosis MRI for radiotherapy  
Couch Soft, often concave 
Maximised for patient comfort 
Needs to be flat, the same as in RT delivery 
Patient positioning Comfortable 
Supine 
As for RT delivery 
Supine 
Immobilisation devices None Combifix knee support to stabilise pelvis 
Bowel artefact 
management 
IM Buscopan 
Anterior abdominal wall compression 
Saturation bands 
IM Buscopan may be used in MRI simulation but may not be 
acceptable during daily treatment within MRI treatment workflow 
Bladder status Empty Full 
Coil placement Pelvic coil centred on tumour Anterior coil supports prevent distortion of external body contour 
Customised MR simulators may incorporate posterior coils into a flat 
couch 
Field strength Increasing strength improves signal to noise, but is 
more expensive and requires more room 
Increasing field strength increases geometric distortion  
Coverage High resolution FOV limited to tumour High resolution FOV must encompass entire tumour target 
Sequences including external body contour required for dose 
calculation 
Preferred  
Sequence 
2d T2w high resolution at tumour with 
<3 mm slice thickness and voxel sixe <1 mm 
Imaging plane perpendicular to the rectum or cervical 
canal  
T2w 3d <1 mm isotropic voxel size for target delineation 
Imaging plane true axial acquired perpendicular to the system 
Geometric accuracy Less important Essential to localise the target 
Electron density/ 
material composition 
information 
Not required Not required in a CT/ MRI combined workflow, but essential in MR-
only simulation and MR treatment workflow 
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FSTable 6: Magnetic resonance image guidance radiotherapy systems  
 Elekta Unity MR Linac 
 
(72, 76) 
ViewRay MRIdian 
Cobalt 60  
(73, 77) 
ViewRay MRIdian 
Linac 
Australian MRI-Linac 
 
(74) 
Canadian Aurora 
Magnet X MR Linac 
(75) 
Magnet 1.5 T closed 0.35 T split bore 0.35 T split bore 1.0 T split bore 0.5 T biplanar rotating 
geometry 
Radiotherapy source 7 MV 3 Cobalt-60 heads 
 
6 MV 6 MV 6 MV 
MLC effective leaf width at 
isocentre  
0.72 cm 1.05 cm 0.83 cm   
MLC maximum leaf speed 6 cm/sec 2.0 ± 0.1 cm/sec > 2cm/ sec   
Magnetic field orientation 
to delivery 
Perpendicular  Perpendicular  Perpendicular  Perpendicular and 
parallel  
Perpendicular and 
parallel 
Bore Size 70 cm 70 cm 70 cm 50 cm 60 cm 
Magnetic field 
homogeneity 
≤ 2.0 ppm over 50x 
50x 45 cm3 
<25 ppm over 45 cm 
DSV  
<25 ppm over 45 cm 
DSV  
  
Maximum imaging field of 
view 
50 cm DSV 50 cm DSV 50 cm DSV   
Maximum treatment field 
size 
57.4x 22 cm2 27.3x 27.3 cm2 27.4x 24.1 cm2   
4D capabilities Yes Yes Yes No No 
Functional imaging  Yes Yes Yes No No 
Treating patients Yes Yes Yes No No 
CE Marked/ FDA approved Yes Yes Yes No No 
MLC= Multileaf collimator 
DSV= Diameter of spherical volume 
Ppm= Parts per million 
 
Table 6
